Published in Mol Cell Biol on October 01, 1996
The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 9.51
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A (2003) 6.37
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev (1998) 5.31
Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci (2008) 4.91
Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J (1999) 3.79
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene (2007) 3.17
Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol (1999) 3.05
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell (2007) 2.75
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov (2013) 2.65
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42
Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev (1998) 2.38
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A (1999) 2.22
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J (1998) 2.04
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res (2012) 2.04
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol (2000) 1.92
Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J (1997) 1.91
ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol (1998) 1.88
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol (2015) 1.88
Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res (2009) 1.86
Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.85
Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol (2000) 1.85
Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol (2001) 1.80
Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell (1999) 1.74
HER2: biology, detection, and clinical implications. Arch Pathol Lab Med (2011) 1.68
Molecular biology of lung cancer. J Thorac Dis (2013) 1.67
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol (2008) 1.65
Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy. Biophys J (2007) 1.64
ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat Cell Biol (2015) 1.62
Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J (1997) 1.58
Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J (1998) 1.57
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol (2010) 1.54
Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J (1998) 1.49
Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Sci Signal (2014) 1.49
The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med (2007) 1.37
Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res (2000) 1.37
Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response. Biophys J (2006) 1.36
Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci U S A (2003) 1.36
Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J Biol Chem (2009) 1.36
The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer (2011) 1.34
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res (2011) 1.34
EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene (2010) 1.30
Activation of ErbB2 receptor tyrosine kinase supports invasion of endothelial cells by Neisseria meningitidis. J Cell Biol (2001) 1.29
ErbB2 is required for ductal morphogenesis of the mammary gland. Proc Natl Acad Sci U S A (2004) 1.29
Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging. Proc Natl Acad Sci U S A (2011) 1.27
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc Natl Acad Sci U S A (2013) 1.22
Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain. Nat Struct Mol Biol (2009) 1.22
ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol (1998) 1.19
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res (2013) 1.18
ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. Proc Natl Acad Sci U S A (1998) 1.17
Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res (2010) 1.16
Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res (2012) 1.14
Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell (2002) 1.14
Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Mol Cell Biol (2003) 1.14
Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol (2009) 1.12
Emerging therapies in gastrointestinal cancers. World J Gastroenterol (2006) 1.11
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. Int J Breast Cancer (2011) 1.10
Increased expression of the integral membrane protein ErbB2 in Chinese hamster ovary cells expressing the anti-apoptotic gene Bcl-xL. Protein Expr Purif (2009) 1.09
Neuregulin-mediated ErbB3 signaling is required for formation of zebrafish dorsal root ganglion neurons. Development (2008) 1.08
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res (2007) 1.08
Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. Br J Cancer (2004) 1.07
Physical-chemical principles underlying RTK activation, and their implications for human disease. Biochim Biophys Acta (2011) 1.06
Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis. BMC Evol Biol (2006) 1.06
Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol (2010) 1.06
The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J (1999) 1.06
ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Res (2008) 1.06
Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res (2012) 1.05
Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int (2012) 1.05
Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer (2007) 1.05
Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene (2005) 1.04
Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med (2011) 1.04
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol (2011) 1.03
Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer (2006) 1.03
HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer (2003) 1.03
A chromosome-centric human proteome project (C-HPP) to characterize the sets of proteins encoded in chromosome 17. J Proteome Res (2012) 1.03
Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements. Biophys J (2008) 1.02
erbB3 is an active tyrosine kinase capable of homo- and heterointeractions. Mol Cell Biol (2013) 1.02
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Res (2005) 1.02
Role of ErbB2 in Corneal Epithelial Wound Healing. Invest Ophthalmol Vis Sci (2004) 1.02
Kinase-mediated quasi-dimers of EGFR. FASEB J (2010) 1.01
The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci U S A (1999) 1.00
p21-activated kinases in Erbb2-positive breast cancer: A new therapeutic target? Small GTPases (2010) 1.00
HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res (2005) 1.00
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol (2011) 1.00
Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells. Biochim Biophys Acta (2010) 1.00
HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells. BMC Cell Biol (2009) 1.00
Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J Biol Chem (2011) 0.99
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis (2012) 0.99
Erbin regulates NRG1 signaling and myelination. Proc Natl Acad Sci U S A (2009) 0.98
Liver regeneration, growth factors, and amphiregulin. Gastroenterology (2005) 0.97
Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Mol Cell Biol (2008) 0.97
Chemopreventive activity of vitamin E in breast cancer: a focus on γ- and δ-tocopherol. Nutrients (2011) 0.96
Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins. PLoS One (2011) 0.96
The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget (2014) 0.95
The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. Trans Am Clin Climatol Assoc (2003) 0.95
Induction of multiple signaling loops by MuSK during neuromuscular synapse formation. Proc Natl Acad Sci U S A (2001) 0.94
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem (1980) 28.03
Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol (1985) 25.52
Improved retroviral vectors for gene transfer and expression. Biotechniques (1989) 19.48
SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science (1991) 12.93
Growth factor receptor tyrosine kinases. Annu Rev Biochem (1988) 8.67
Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science (1985) 6.56
Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol (1994) 5.24
The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta (1994) 4.92
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A (1994) 4.51
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol (1994) 4.49
SH2 and SH3 domains. Curr Biol (1993) 4.17
Signalling by receptor tyrosine kinases. Annu Rev Biochem (1993) 4.11
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene (1995) 4.10
Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry (1987) 3.94
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem (1994) 3.46
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (1989) 3.27
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol (1995) 3.09
Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J (1995) 2.87
A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell (1994) 2.64
Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature (1993) 2.63
The erbB3 gene product is a receptor for heregulin. J Biol Chem (1994) 2.63
Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell (1990) 2.58
Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J Biol Chem (1994) 2.44
Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci U S A (1988) 2.31
Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell (1989) 2.30
Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer (1987) 2.27
EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. EMBO J (1988) 2.15
Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol (1995) 2.13
Transforming growth factor-alpha. A model for membrane-anchored growth factors. J Biol Chem (1990) 2.00
Neu and its ligands: from an oncogene to neural factors. Bioessays (1993) 2.00
ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J Biol Chem (1994) 1.88
Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO J (1988) 1.86
Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry (1990) 1.81
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A (1991) 1.78
Isoform-specific induction of actin reorganization by platelet-derived growth factor suggests that the functionally active receptor is a dimer. EMBO J (1989) 1.76
Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J (1993) 1.74
The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res (1992) 1.64
Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol Cell Biol (1994) 1.64
HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J (1989) 1.63
Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem (1994) 1.63
A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. Protein Eng (1990) 1.62
Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J Biol Chem (1995) 1.57
The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene (1994) 1.51
Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. Biochem J (1990) 1.49
Characteristics of cell lines established from human gastric carcinoma. Cancer Res (1990) 1.49
An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem (1996) 1.43
The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol (1990) 1.42
A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. EMBO J (1989) 1.40
HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers. J Biol Chem (1996) 1.40
A subdomain in the transmembrane domain is necessary for p185neu* activation. EMBO J (1992) 1.34
Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J (1991) 1.33
NDF/heregulin stimulates the phosphorylation of Her3/erbB3. FEBS Lett (1994) 1.29
Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc Natl Acad Sci U S A (1990) 1.25
Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kinases. J Biol Chem (1995) 1.19
The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell (1995) 1.17
ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes. Oncogene (1995) 1.06
An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity. J Biol Chem (1992) 1.01
Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase. Cancer Treat Res (1994) 0.86
A new model for the interaction of EGF-like ligands with their receptors: the new one-two. Eur J Cancer (1994) 0.86
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 17.70
TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res (2000) 15.70
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (1984) 14.21
The TRANSFAC system on gene expression regulation. Nucleic Acids Res (2001) 13.63
ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell (2000) 9.13
Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature (1986) 7.90
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell (1999) 6.79
Expanding the TRANSFAC database towards an expert system of regulatory molecular mechanisms. Nucleic Acids Res (1999) 6.70
A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet (1996) 6.58
Natural engineering principles of electron tunnelling in biological oxidation-reduction. Nature (1999) 6.38
Revealing the maximum strength in nanotwinned copper. Science (2009) 6.27
Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol (1998) 5.54
Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3) Nature (1996) 5.32
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev (1998) 5.31
Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest (1994) 5.12
Expression of naphthalene oxidation genes in Escherichia coli results in the biosynthesis of indigo. Science (1983) 5.10
Acquisition of sequences homologous to host deoxyribonucleic acid by closed circular simian virus 40 deoxyribonucleic acid. J Virol (1972) 4.81
Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A (1996) 4.76
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J (1996) 4.26
Cdc25 cell-cycle phosphatase as a target of c-myc. Nature (1996) 4.23
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry (1987) 3.94
Development of microsatellite markers and characterization of simple sequence length polymorphism (SSLP) in rice (Oryza sativa L.). Mol Gen Genet (1996) 3.75
CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med (2000) 3.62
Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol (1998) 3.61
Functionalized graphene sheets for polymer nanocomposites. Nat Nanotechnol (2008) 3.45
SVM-Prot: Web-based support vector machine software for functional classification of a protein from its primary sequence. Nucleic Acids Res (2003) 3.34
Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J Respir Cell Mol Biol (1994) 3.32
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett (1997) 3.23
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry (1987) 3.20
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene (2000) 3.12
Regulation of CSF1 promoter by the SWI/SNF-like BAF complex. Cell (2001) 3.10
Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem (2000) 3.06
Evolutionarily conserved sequences on human chromosome 21. Genome Res (2001) 2.95
Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. J Biol Chem (1983) 2.94
Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int (2007) 2.92
Expression of epidermal growth factor receptors in human brain tumors. Cancer Res (1984) 2.83
Methylated simian virus 40-specific RNA from nuclei and cytoplasm of infected BSC-1 cells. Proc Natl Acad Sci U S A (1975) 2.81
Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest (1992) 2.80
An information-based sequence distance and its application to whole mitochondrial genome phylogeny. Bioinformatics (2001) 2.80
Parallel genotyping of human SNPs using generic high-density oligonucleotide tag arrays. Genome Res (2000) 2.79
Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab (2001) 2.79
Filamentous growth of Candida albicans in response to physical environmental cues and its regulation by the unique CZF1 gene. Mol Microbiol (1999) 2.74
The forgotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor. J Biol Chem (2000) 2.67
Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest (1991) 2.65
Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell (1992) 2.62
Perceived discrimination and early substance abuse among American Indian children. J Health Soc Behav (2001) 2.60
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J Biol Chem (1999) 2.57
A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev (1993) 2.53
Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A (1998) 2.48
The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci (2004) 2.47
Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol (2000) 2.47
The avian beta-adrenergic receptor: primary structure and membrane topology. Proc Natl Acad Sci U S A (1986) 2.45
Agrobacterium-Mediated Transformation of Fusarium oxysporum: An Efficient Tool for Insertional Mutagenesis and Gene Transfer. Phytopathology (2001) 2.43
An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature (1997) 2.42
Synthesis of all the gene products of the reovirus genome in vivo and in vitro. Cell (1975) 2.42
p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene (2001) 2.40
English language use as a risk factor for smoking initiation among Hispanic and Asian American adolescents: evidence for mediation by tobacco-related beliefs and social norms. Health Psychol (2000) 2.36
Structure of the trp RNA-binding attenuation protein, TRAP, bound to RNA. Nature (1999) 2.35
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res (2000) 2.33
Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron (1997) 2.33
A whole genome association study of neuroticism using DNA pooling. Mol Psychiatry (2007) 2.30
A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol Cell Biol (1991) 2.27
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother (1998) 2.23
NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene (2011) 2.22
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A (1999) 2.22
Developmental expression of two murine fibroblast growth factor receptors, flg and bek. Development (1991) 2.16
Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett (2001) 2.15
The role of social networks and media receptivity in predicting age of smoking initiation: a proportional hazards model of risk and protective factors. Addict Behav (1999) 2.14
Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A (1999) 2.14
The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J Biol Chem (1999) 2.13
The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci U S A (1993) 2.11
Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab (1996) 2.10
Regulation of cell proliferation by epidermal growth factor. CRC Crit Rev Biochem (1983) 2.09
Tic20 and Tic22 are new components of the protein import apparatus at the chloroplast inner envelope membrane. J Cell Biol (1998) 2.08
Defective DNA polymerase-delta proofreading causes cancer susceptibility in mice. Nat Med (2001) 2.08
A gene expression screen in zebrafish embryogenesis. Genome Res (2001) 2.08
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res (2000) 2.07
Localization of an ataxia-telangiectasia gene to an approximately 500-kb interval on chromosome 11q23.1: linkage analysis of 176 families by an international consortium. Am J Hum Genet (1995) 2.07
The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res (1998) 2.06
Detection of antigen-antibody binding events with the atomic force microscope. Biochemistry (1997) 2.05
Pain relief during panretinal photocoagulation for diabetic retinopathy: a national survey. Eye (Lond) (2009) 2.05
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J (1998) 2.04
PharmGED: pharmacogenetic effect database. Clin Pharmacol Ther (2007) 2.02
Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation, and maturation of rat Schwann cell precursors. Neuron (1995) 2.02